T Stamp Inc (NASDAQ:IDAI, EURONEXT:AIID) dba Trust Stamp posted a 62% rise in second-quarter net recognised revenue, driven by higher customer activity and growth in its financial institution client base.
The AI-powered identity services provider reported net recognized revenue of $810,000 for the three months ended June 30, up from $500,000 a year earlier, with an additional $290,000 earned from its QID services contract but deferred under accounting rules.
Ideal Power Inc (NASDAQ:IPWR) said on Thursday its first design win customer is close to completing prototype testing for a B-TRAN-enabled solid-state circuit breaker (SSCB) ahead of a planned rollout later this year.
“Our first design win customer is nearing completion of their B-TRAN-enabled solid-state circuit breaker (SSCB) prototype testing,” CEO Dan Brdar said in a statement.
Lancaster Resources Inc (CSE:LCR, OTCQB:LANRF) said it has commenced desk and field work at its Lake Cargelligo gold project in New South Wales, Australia, the first step toward completing its maiden National Instrument 43-101 Technical Report.
The 28,768-hectare project sits in the Lachlan Fold Belt, a region known for high-grade gold and silver deposits.
Arizona Gold & Silver Inc (TSX-V:AZS, OTCQB:AZASF) has reported new drilling results from its ongoing program at the Philadelphia project in Arizona, including the intersection of a 10-metre section of unbrecciated banded and massive quartz vein.
The intercept was encountered in core hole PC25-156, which cut approximately 10 metres of intact epithermal quartz vein within a broader 35.7-metre zone of quartz vein and quartz vein breccia.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has enrolled and dosed the first participant in its Phase 2a clinical trial evaluating intranasal foralumab in patients with Multiple System Atrophy (MSA).
The trial is being conducted at Brigham and Women’s Hospital in Boston.
Volato Group Inc said on Thursday it is on track to close its planned all-stock merger with M2i Global (OTC:MTWO) in the fourth quarter of 2025, as the private aviation company reported its second consecutive quarterly profit and sharply reduced liabilities.
A joint integration team is finalizing readiness plans across finance, IT, cybersecurity, procurement and compliance, with early cost synergies expected to be implemented immediately after the deal closes.
Charbone Hydrogen Corporation (TSX-V:CH, OTCQB:CHHYF) reported multiple milestones this week at its flagship Sorel-Tracy green hydrogen production facility in Québec, including the completion of electrical and water supply infrastructure, as well as the start of civil construction work.
The company said Hydro-Québec has completed the electrical interconnection of the site, linking the distribution network to on-site power infrastructure following the installation of a metering station three weeks earlier.
Candel Therapeutics Inc (NASDAQ:CADL) said on Thursday it plans to seek US approval for its lead cancer drug CAN-2409 in late 2026, after a key Phase 3 prostate cancer trial succeeded and the FDA granted it Regenerative Medicine Advanced Therapy (RMAT) status.
The clinical-stage biotech reported a narrower second-quarter loss, backed by stronger trial results and financing that will help support launch readiness activities.
Protalix Biotherapeutics Inc (NYSE-A:PLX) reported higher quarterly revenue and reaffirmed its long-term growth outlook on Thursday, pointing to expanding demand for its Fabry disease treatment Elfabrio and upcoming clinical milestones for its pipeline.
The Israeli biopharmaceutical company said revenue from selling goods rose 16% to $15.4 million in the quarter ended June 30, driven largely by increased sales of Elfabrio to Italian drugmaker Chiesi.
OptiBiotix Health PLC (AIM:OPTI, OTC:OPBXF) saw its shares jump around 14% on Thursday, after it announced the launch of SlimBiome in Hydroxycut Hunger Control, a product from what it says is America’s top-selling weight loss supplement brand. The launch follows the first order announced in April 2025.
The product is now available online and in major retailers such as Walmart. Marketing includes results from two OptiBiotix studies showing reductions in hunger of 74% and 83%. Order for a second product application have been received, with launch planned later this year.
Falcon Oil & Gas Ltd (AIM:FOG, TSX-V:FO) shares climbed 10% on Thursday, as the explorer and its partners in the Beetaloo project secured Native Title Holder consent to sell gas.
The agreement covers sales from exploration permits EP98 and EP117 of up to 60 terajoules per day from the proposed Shenandoah South pilot project over three years, subject to terms and ministerial approval.
A partnering agreement between US-based market access consultancy PRO-spectus and Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) will drive marketing, market access, and reimbursement of LDX’s flagship point-of-care diagnostic, FebriDx®.
With US Medicare reimbursement already in place, Lumos is now focused on securing coverage from private insurance payors, which make up around 60% of the US health insurance market and cover more than 170 million Americans. This includes both major insurers controlling nearly half the market and hundreds of smaller players requiring a targeted approach.